RxDoctor Payments Data

Eric Wien, MD

Hepatology · Spokane, WANPI 1952806804

Payments from drug & device makers

$1,373in general payments, 2019–2025

Across 33 payments — averaging $41.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$225
  • GSK$184
  • Madrigal Pharmaceuticals$161
  • Mallinckrodt Hospital Products Inc.$146
  • Intercept Pharmaceuticals, Inc.$144
  • Novo Nordisk$123
  • plus $389 from 11 others

What the payments were for

  • Food & beverage$1,373100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$57,633
Medicare patients
221
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin52$159,975
Ursodiol90$14,107
Tacrolimus89$9,272
Mycophenolate Mofetil45$3,243
Lactulose61$3,035
Azathioprine47$2,027
Budesonide DrBudesonide15$1,355
Spironolactone68$1,140
Midodrine Hcl12$738
ConstuloseLactulose13$694
Carvedilol77$505
Furosemide89$383
Prednisone26$354
Calcitriol17$281
Hydroxyzine Hcl12$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$50$159,97552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Washingtonon file to place this against a meaningful peer group, so we don't.

Other hepatology in Spokane

Where these figures come from

Is this you, or does something look wrong? →